Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics.

Yu J, Dabbs DJ, Shuai Y, Niemeier LA, Bhargava R.

Am J Clin Pathol. 2011 Jul;136(1):88-97. doi: 10.1309/AJCP7URIW0QETTAT.

PMID:
21685036
[PubMed - indexed for MEDLINE]
Free Article
2.

The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

Fadare O, Wang SA, Hileeto D.

Hum Pathol. 2008 Mar;39(3):331-6. doi: 10.1016/j.humpath.2007.07.014.

PMID:
18261623
[PubMed - indexed for MEDLINE]
3.

Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.

Kinsella MD, Nassar A, Siddiqui MT, Cohen C.

Int J Clin Exp Pathol. 2012;5(6):530-6. Epub 2012 Jul 29.

PMID:
22949935
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report.

Manucha V, Khilko N, Reilly K, Zhang X.

Int J Clin Exp Pathol. 2011 Jan 30;4(2):200-5.

PMID:
21326816
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.

Turashvili G, Bouchalova K, Bouchal J, Kolar Z.

Cesk Patol. 2007 Jul;43(3):87-92.

PMID:
17821836
[PubMed - indexed for MEDLINE]
6.

The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.

Tong LC, Nelson N, Tsourigiannis J, Mulligan AM.

Am J Surg Pathol. 2011 Apr;35(4):545-52. doi: 10.1097/PAS.0b013e31820e6237.

PMID:
21358301
[PubMed - indexed for MEDLINE]
8.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
[PubMed - indexed for MEDLINE]
9.

The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.

Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, Kreike B, Reis-Filho JS.

J Pathol. 2010 Jan;220(1):45-57. doi: 10.1002/path.2629.

PMID:
19877120
[PubMed - indexed for MEDLINE]
10.

[Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].

Zheng S, Zhang BL, Xiao T, Zou SM, Xue LY, Luo W, Guo L, Liu XY, Lü N.

Zhonghua Bing Li Xue Za Zhi. 2011 Jul;40(7):465-70. Chinese.

PMID:
22088373
[PubMed - indexed for MEDLINE]
11.

Histologic subtypes of invasive lobular carcinoma in correlation with tumor status and hormone receptors.

Mise I, Vucić M, Maricević I, Sokcević M, Curić-Jurić S.

Acta Clin Croat. 2010 Sep;49(3):275-81.

PMID:
21462816
[PubMed - indexed for MEDLINE]
12.

Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.

Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ.

Am J Surg Pathol. 2008 Nov;32(11):1721-6. doi: 10.1097/PAS.0b013e31817dc3a6.

PMID:
18769331
[PubMed - indexed for MEDLINE]
13.

[Tubulolobular carcinoma of breast: a clinicopathologic study of 8 cases].

Shi J, Liang ZY, Meng ZL, Luo YF, Cao JL, Yang CM, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):681-5. doi: 10.3760/cma.j.issn.0529-5807.2012.10.008. Chinese.

PMID:
23302310
[PubMed - indexed for MEDLINE]
14.

Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M.

Pathol Oncol Res. 2006;12(2):83-6. Epub 2006 Jun 24.

PMID:
16799708
[PubMed - indexed for MEDLINE]
Free Article
15.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

PMID:
19239686
[PubMed - indexed for MEDLINE]
Free PMC Article
16.
17.

[Invasive lobular carcinoma of basal-like subtype of breast: a clinicopathologic analysis].

Zhang LY, Gao LX, Liu G, Yang GZ, Cheng J, Ding HY.

Zhonghua Bing Li Xue Za Zhi. 2013 Sep;42(9):599-603. Chinese.

PMID:
24314245
[PubMed - indexed for MEDLINE]
18.

Invasive lobular carcinoma: to grade or not to grade.

Bane AL, Tjan S, Parkes RK, Andrulis I, O'Malley FP.

Mod Pathol. 2005 May;18(5):621-8.

PMID:
15605082
[PubMed - indexed for MEDLINE]
Free Article
19.

Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.

Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.

J BUON. 2012 Apr-Jun;17(2):277-83.

PMID:
22740206
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk